Over the past decade, neoadjuvant chemotherapy (NAC) has become the standard of care for patients with high-risk early-stage BC, mostly triple negative BC (TNBC), HER2-positive tumors but also hormone receptor (HR)-positive BC exhibiting high-risk features such as clinical nodal involvement. This evidence concerns the gene ERBB2 and breast cancer.